Fadi Haddad, MD
@FadiHaddad_MD
Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston
Very much looking forward to this meeting. Looking forward to great discussions and presentations from key US and international leaders on AML & ALL. Hoping you can join! @_MDEducation @jaltmanmd @TapKadia @doctorpemm @Ramikomrokji
🗓 Next Week: We're just days away from the 4th Annual AML-ALL US Focus Meeting 2025, taking place July 10–12 at the Marina del Rey Marriott, CA. A huge thank you to our co-chairs for curating an outstanding agenda and world-class faculty: ▪️ @Daver_Leukemia – MD Anderson Cancer…
📢 Check our latest podcast on #MRD in #Leukemia where I discuss the latest updates with @doctorpemm from @MDAndersonNews
In the latest Cancerwise podcast episode, Drs. Naveen Pemmaraju and Fadi Haddad explain how minimal residual disease is helping doctors monitor leukemia more precisely and personalize treatment. Listen to what the future of MRD research could mean for patients:…
🏃➡️ Walking for the #CTREC 2025 in beautiful #Damasucs to raise funds for fighting #cancer 🙏 Honoring cancer #patients & #survivors 💰 $105K raised to support #research on #sarcoma #leiomyosarcoma🎗️ with the best @NassifElise 🥇 Support below 👇 creepertrailridetoendcancer.com
📢 Updates on the outcome of #CML failing to achieve the milestones presented at #PPLC25 🔹Not reaching the failure milestone at 6 & 12 mo still associated with decent survival 🔹Warning/failure could be accepted in some patients where other tx are not feasible #leusm @OncoAlert
📢 Out in @JournalCancer ➡️ Updates on the mamagement of #CML in 2025 💊 Treatment options 1/2+ lines 👌 Optimal biologic dosing 💰 Cost of therapy 🌍 Perspective from experts accross different countries Article available below ⬇️ #leusm @OncoAlert acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…
✈️ with 👶 is challenging Today on #UnitedAirlines #Denver➡️#Houston all passengers & crew were supportive, except for #Mallory Mallory was the most non-empatehtic flight attendant ever‼️ @united should train their personnel when to follow or not their protocols‼️ #shameful
Excellent summary slides from @NitinJainMD on updates & future directions in chronic lymphocytic #leukemia #CLL #leusm @OncoAlert ‼️Exciting combination therapies & time-limited therapies coming
Happy & honored to join giants in Leukemia Care at the #PPLC25 meeting at #Maui 🔹Updates on the management of chronic & acute #leukemia 🔹Exciting strategies under development 🎯 Same goal 🟰 improve patient outcomes 🙏 @NitinJainMD @GCC_Cortes #leusm #CML
Moving away towards disease modification in #myelofibrosis @doctorpemm reviewing the different strategies from combos to newer drugs & immune therapies at #PPLC2025 Exiciting years ahead in the #MPN field with lot of advancements happening... #mpnsm #leusm
Recent updates & great discussions in #ALL at the #PPLC2025 chaired by @NitinJainMD 🔹CNS diease by @RyanCassaday 🔹Ph + & - ALL by @LuskinMarlise 🔹BCL-2 / BCL-XL inhibitors by @NitinJainMD
Rare side effect of nelarabine - rhabdomyolysis - reported by @NitinJainMD
👉👉We report case series of 6 patients with T-ALL/LBL who developed rhabdomyolysis after receiving nelarabine 👉 Check CK if pt develops myalgia, unexplained rise in creatinine while on nelarabine @Dr_MSU @DrHKantarjian tandfonline.com/doi/full/10.10…
📢 Out in @NEJMEvidence 👫N=1132 pts; age 18-60 🔹ND #AML 🔹Consolidation with IDAC vs HIDAC 🔹5-yr OS = 59% vs 58% 🔹Lower incidence of myelosuppressio & AEs with IDAC ➡️ IDAC non inferior to HIDAC #leusm @OncoAlert evidence.nejm.org/doi/pdf/10.105…
I was so excited to join @VJOncology at #ASCO25 with @MDAndersonNews to dig into neoadjuvant endocrine therapy vs. chemo in Stage II/III ER+/HER2– lobular carcinoma! 🌟 🎥 I promise, it’s a quick watch with my top takeaways and why this matters for #ILC patients. 👉 Tune in and…
On June 23, 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic EGFR-mutated non-small cell #LungCancer ( #NSCLC ) who have previously received EGFR-directed therapy and platinum-based chemotherapy.…
📢 The long awaited outcome of the #VERONA trial is out 🔹Randomized Ph 3 trial 👫Aza + Ven versus Aza + placebo in newly diagnosed high-risk #MDS ⛔ Primary endpoint of OS not met (HR 0.9) ❓What does this mean to the MDS & #leukemia community? #leusm news.abbvie.com/2025-06-16-Abb…
You will work endless hours. You will sacrifice your health. You will miss important events, & you will expect all of this struggle to eventually pay off. And then?…it doesn’t. Over and over again. Unti, one day,…it does. That’s what success REALLY looks like.
📈The role of #socialmedia in the medical field continues to grow, whetger for teaching purposes, patient & caregiver education, or CME... 👉 Recent paper by @SibaElHussein & @sanamloghavi on the role of social media in #HemPath #leusm @OncoAlert ⤵️ link.springer.com/article/10.100…
A GREAT START OF #EHA25 🩸 Lets Go to #MEDTRACK for Stats Follow MEDTRACK HERE👉 @OncoReporte ⚕️ my.medical.watch/oncoalert/hash… MEDTRACK brought to you by @OncoAlert 🚨 & @MedicalwatchFTW ⭐️GREAT ENGAGEMENT ON DAY ONE Metrics from June 11-12, 2025 EHA Contributors…
📽️ All you need to know about #MRD in #Leukemia 🙂 Honored to discuss the past, present, & future of MRD with @doctorpemm 🏅 🙏 Special thanks to @MDAndersonNews #CancerWise #Podcast team 👉 Watch the full episode on #YouTube ⤵️ youtu.be/7yDiInoPOUQ?si… @OncoAlert #leusm
#Leukemia Fellows are the dynamo of our program at @MDAndersonNews 🎖️ Excited to be at their graduation 🔥 They will lead the future of leukemia care around the world 🌎 @DrHKantarjian @TapKadia @garciamanero @doctorpemm @HannahGoulart #leusm #fellowship
👉👉👉Spectacular moment celebrating 🙏 our wonderful graduating Leukemia Fellows together yesterday evening ! @MDAndersonNews #leusm #endcancer @DrHKantarjian @garciamanero @TapKadia